Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 5,394 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 5,394 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.00, for a total value of $107,880.00. Following the transaction, the insider owned 115,005 shares in the company, valued at approximately $2,300,100. This trade represents a 4.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Thursday, April 30th, Gwenn Hansen sold 3,214 shares of Nurix Therapeutics stock. The shares were sold at an average price of $16.65, for a total transaction of $53,513.10.

Nurix Therapeutics Price Performance

Shares of NRIX opened at $22.46 on Friday. The company has a market capitalization of $2.32 billion, a PE ratio of -7.11 and a beta of 1.86. Nurix Therapeutics, Inc. has a one year low of $8.19 and a one year high of $23.09. The company’s fifty day moving average price is $16.86 and its 200 day moving average price is $16.99.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Wednesday, April 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). The firm had revenue of $6.25 million for the quarter, compared to the consensus estimate of $14.25 million. Nurix Therapeutics had a negative net margin of 411.37% and a negative return on equity of 64.21%. Analysts anticipate that Nurix Therapeutics, Inc. will post -2.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on NRIX shares. Wells Fargo & Company cut Nurix Therapeutics from an “overweight” rating to a “hold” rating and reduced their price objective for the company from $28.00 to $25.00 in a research report on Monday, June 8th. Needham & Company LLC reiterated a “buy” rating and set a $34.00 target price on shares of Nurix Therapeutics in a research note on Monday, June 15th. Robert W. Baird increased their price target on shares of Nurix Therapeutics from $26.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. BTIG Research raised their price target on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Finally, Jefferies Financial Group boosted their price objective on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, June 8th. Fourteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $32.20.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NRIX. Larson Financial Group LLC raised its position in Nurix Therapeutics by 339.0% in the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after purchasing an additional 1,190 shares in the last quarter. Intesa Sanpaolo Wealth Management acquired a new stake in Nurix Therapeutics during the fourth quarter valued at approximately $31,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Nurix Therapeutics in the 4th quarter valued at approximately $33,000. KBC Group NV acquired a new position in shares of Nurix Therapeutics in the 1st quarter worth approximately $34,000. Finally, Wexford Capital LP acquired a new position in shares of Nurix Therapeutics in the 3rd quarter worth approximately $41,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.